The overall objective of Cancer Center Planning and Evaluation is to provide effective and integrated processes to ensure that the Cancer Center fulfills its mission set by the NCI and the University of Alabama at Birmingham. These planning activities involve all of our Senior Leaders, Program Leaders, and on occasion, members of the Cancer Center. Major planning occurs in the Director's Council, made up of Senior Leadership, with significant advice in planning and evaluation from the External and Internal Advisory Committees. Evaluation consists of both external review by the External Advisory Committee, and two avenues of critical internal review. Internal review comes both from review of the entire CCC by an Internal Advisory Committee made up of leaders across the UAB campus, and evaluation of the shared facilities by an internal committee. Additional planning occurs in the bi-monthly Program Leaders meeting, the annual Program and Senior Leadership Retreat, and the biennial Cancer Center Strategic Planning Retreat. Some ofthe specific planning processes include the following. ? Our External Advisory Committee (EAC) consists of ten members with extensive Cancer Center leadership and nationally recognized expertise required to critically evaluate and advise regarding the Cancer Center's programmatic and organizational development. The EAC meets annually. ? The Center holds an annual center-wide research retreat in order to stimulate transdisciplinary research collaboration and program development as well as an annual priority and strategic planning retreat for identification of Cancer Center scientific priorities, recruitment needs, and for major program evaluation and development. This retreat includes leadership on an annual basis and the entire Cancer Center membership on a biennial basis. ? The Cancer Center also sponsors community-based conferences to facilitate interactions with the community and providers who can be extremely important to our clinical and prevention trials. ? The major planning and evaluation activity occurs in the monthly Director's Council composed of all Senior Leaders in the Cancer Center.
A Comprehensive Cancer Center represents a major investment by the NCI, and, by extension, the taxpayers of the United States. Effective planning and evaluation are critical to assure that the goals of the NCI and ofthe Public Health Service are being met. Our Planning and Evaluation processes are designed to meet that need.
|Fauci, Janelle M; Sabbatino, Francesco; Wang, Yangyang et al. (2014) Monoclonal antibody-based immunotherapy of ovarian cancer: targeting ovarian cancer cells with the B7-H3-specific mAb 376.96. Gynecol Oncol 132:203-10|
|Carson, Tiffany L; Hardy, Claudia M; Greene, Eva et al. (2014) Considerations for bio-specimen collection among black women residing in the rural Deep South participating in a cancer prevention study. J Community Genet 5:257-63|
|Kim, Hyunki; Rigell, Christopher J; Zhai, Guihua et al. (2014) Antagonistic effects of anti-EMMPRIN antibody when combined with chemotherapy against hypovascular pancreatic cancers. Mol Imaging Biol 16:85-94|
|Devine, D J; Rostas, J W; Metge, B J et al. (2014) Loss of N-Myc interactor promotes epithelial-mesenchymal transition by activation of TGF-*/SMAD signaling. Oncogene 33:2620-8|
|Sonpavde, Guru; Willey, Christopher D; Sudarshan, Sunil (2014) Fibroblast growth factor receptors as therapeutic targets in clear-cell renal cell carcinoma. Expert Opin Investig Drugs 23:305-15|
|Saini, Reshu; Hoyt, Kenneth (2014) Recent developments in dynamic contrast-enhanced ultrasound imaging of tumor angiogenesis. Imaging Med 6:41-52|
|Shim, Eun-Hee; Livi, Carolina B; Rakheja, Dinesh et al. (2014) L-2-Hydroxyglutarate: an epigenetic modifier and putative oncometabolite in renal cancer. Cancer Discov 4:1290-8|
|Gan, Yujun; Buckels, Ashiya; Liu, Ying et al. (2014) Human GH receptor-IGF-1 receptor interaction: implications for GH signaling. Mol Endocrinol 28:1841-54|
|Johnson, David H; Wilson, W William; DeLucas, Lawrence J (2014) Protein solubilization: a novel approach. J Chromatogr B Analyt Technol Biomed Life Sci 971:99-106|
|Ramos, Theresa N; Bullard, Daniel C; Barnum, Scott R (2014) ICAM-1: isoforms and phenotypes. J Immunol 192:4469-74|
Showing the most recent 10 out of 364 publications